Back ground: Unresectable colorectal liver metastases can be resected af ter re sponse to che mo therapy. The use of neoadjuvant che mo ther apy with or with out tar geted monoclonal an ti bod ies increases the pro por tion ofofresectable liver me tasta sis and con ferred a long term sur vival of 40%. Meth ods: The cur rent on go ing stud ies re gard ing neodjuvant treat ment strat e gies aim ing to increase a pro por tion of pa tients with resectable liver metastases is go ing to be pre sented. Re sults: Periop era tive che mo ther apy with FOLFOX4 is com pat i ble with ma jor liver sur gery and re duces the risk of events of pro gres sion free sur vival in resected patients. The re sults of the CELIM study con firm a favour able long-term sur vival for pa tients with ini tially suboptimal or unresectable colorectal liver me tas ta sis who re spond to con ver sion ther apy and un dergo second ary re sec tion. The New EPOC ran dom ised trial does not sup port the ad di tion of cetuximab to che mother apy and sur gery for op er a ble colorectal liver metas ta sis in KRAS exon 2 wild-type pa tients. Con clusion: The abil ity of anti-epi der mal growth fac tor re cep tor agents to in crease re sponse rate and re section when added to che mo ther apy has been clearly shown in a num ber of tri als. The re sec tion rates are higher with che mo ther apy plus Cetuximab, in general, a con ver sion is con trib utes to the better over all sur vival.
G enerally, met a static colorectal can cer rep re sents an in cur able sit u a tion for which only pal lia tive op tions (e.g.: best sup port ive care, pal lia tive che mo ther apy) should be con sid ered. How ever, there are spe cific circum stances where an at tempt at metastastectomymay be pos si ble and where five-year sur viv als may reach 40 percent. Such treat ment re quires in volve ment of a multidisciplinary team that should in clude a hepatobiliary sur geon, tho racic sur geon, and oncologist. The epi der mal growth fac tor re cep tor (EGFR) and the vas cu lar en do thelial growth fac tor (VEGF) or its re cep tor (VEGFR) rep resents a very im por tant mo lec u lar tar get in pa tients with ad vanced colorectal can cer (mCRC), which has been proved in sev eral clin i cal stud ies [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . How ever, the ben efit from anti-EGFR monoclonal an ti bod ies such as cetuximab or panitumumab has been shown only in patients with wild-type K-RAS 5, 6 . The mutational sta tus of K-RAS had no prog nos tic ef fect in pa tients re ceiv ing best sup port ive care (BSC) alone, in di cat ing [4] [5] [6] its role as a pre dic tive biomarker for anti-EGFR an ti body ef fi cacy, thus in clud ing the ge netic test ing for so matic mu ta tions in K-RAS in pa tients with mCRC as a rou tine clin i cal prac tice also in S3-quideline 11 .
Pa tients and Meth ods:
The S-3 Quidelines from June 2013 sug gest that the liver me tas ta sis, po ten tially R0-resectable should be resected with the sug ges tion grade A and level of ev idence of 3b. The Ger man ex perts de fined the resectability of liver me tas ta sis ac cord ing to mod i fied Fong-score if the extrahepatic me tas ta sis are not pres ent, if less that 70% of liver tis sue is in volved, if less than 3 liver veins and less than 7 liver seg ments are in volved, when no liver in suf fi ciency od Child-B or Child -C Liver cir rho sis is pres ent and no se vere dis eases are present. The ESMO also de fined the groups of liver me tas tasis ac cord ing to their resectability. The first ran dom ised data re gard ing the role of perioperative che mo ther apy in resectable liver me tas ta sis have been pub lished from the EORTC study show ing sig nif i cant better over all sur vival (OS) in pa tients with perioperative che mo ther apy the OS and dis ease free sur vival (DFS) in these patients.In ad di tion in a num ber of pa tients (4-9%) achieved a com plete patho log i cal re mis sion 13 . The over all response rate in phase III stud ies and in big num ber of pa tients has been de scribed in cou ple of stud ies from 38 to 66% (Ta ble 1). The re sults of dif fer ent Phase II Stud ies in "only liver" pa tients are also prom is ing (re sponse rate from 57-78% of pa tients) (Ta ble 2). In the CEtuximab in neoadjuvant treat ment of unresectable colorectal Liver Metastases (CELIM) study, pa tients were ran dom ized to re ceive ei ther FOLFOX/cetuximab or FOLFIRI /cetuxi mab 3 . The re sults have shown that the pa tients who under went R0 re sec tion achieved better me dian OS than those who did not. The me dian DFS for R0 resected patients was 9,9 months and the 5-year OS rate was 46,2%, be ing prob a bly the most im por tant re sult of this trial, con firm ing in a multicentre, ran dom ized study the value of in ten sive "con ver sion che mo ther apy". Of those patients de fined as not-resectable be fore the study treatment, 34% fi nally un der went R0 re sec tion and an ad ditional 12% un der went R1 re sec tion. In crease re sponse rates and higher re sec tion rates have been de scribed in pa tients with K-RAS wild-type tu mours who re ceived cetuximab plus FOLFIRI or FOLFOX in both the CRYS -TAL and OPUS stud ies, which en rolled pa tients with both only-liver and non-liver lim ited me tas ta sis 4 .
DIS CUS SION:
Only a cou ple of years ago, the pa tients with met a static colorectal can cer have been re garded as in cur able. The 5 year OS rate of al most 45% in pa tients re ceiv ing an inten sive "con ver sion che mo ther apy" to gether with liver sur gery and R0 re sec tion is the most im por tant re sult in the last de cade in the field of met a static co lon can cer. The find ing that pa tients with unresectable liver me tas tasis can be come resectable af ter re spond ing to che mo therapy and have a better long term out come than che mo therapy alone 13 has led to the in tro duc tion of the con cept of "con ver sion or down siz ing che mo ther apy". It has been also shown that the re sponse of che mo ther apy cor re lates with a re sec tion rate, thus in di cat ing that the prior che mother apy or the com bi na tion with immunotherapy has a cen tral role in the con ver sion che mo ther apy.
Cetuximab, the anti-EGFR an ti body im proves both the over all sur vival and re sponse rate when com bined with che mo ther apy in pa tients whose tu mours are with out K-RAS mu ta tion. The ad di tion of bevacizumab, an an tibody against VGFR to oxaliplatin-based che mo ther apy sig nif i cantly im proved PFS in thisfirst-line trial in patients with MCRC, how ever over all sur vival dif fer ences did not reach sta tis ti cal sig nif i cance 5, 6 . In ad di tion, it has been shown that thetreatment con tin u a tion un til dis ease pro gres sion may be nec es sary in or der to op ti mize the con tri bu tion of bevacizumab to ther apy. It has been also shown that there was noincreased bleed ing risk in patients re ceiv ing bevacizumab and con com i tant anticoagulation ther apy com pared with con trol group of pa tients. The sim i lar re sults have been also ob tained in ran domized, phase 3 study in el derly pa tients in com bi na tion with capecitabine (AVEX) 16 . Panitumumab, anti EGFR an ti body have shown that panitumumab-FOLFOX4 was well tol er ated and sig nif icantly im proved PFS in pa tients with WTKRAS tu mors and un der scores the im por tance of KRAStest ing for patients with mCRC (PRIME Study) 10 . The new AIO Study (Pan aMa) which has been also ini ti ated in our oncolog ical cen ter (OZN) has the aim to com pare in the multicenterrandomised study the ef fect of panitumumab in pa tients with mCRC.
SUM MARY DA LI METASTAZIRANI KOLOREKTALNI KARZINOM MOŽE DA SE IZLEÈI?
Uvod: Primarno neresektabilne metastaze kolorektalnog karcinoma u jetri mogu se resecirati posle primenjene citostatske terapije. Primena neoadjuvantne (perioperativne) citostatske terapije u kombinaciji sa monoklonskim antitelima poveaeava procenat resektabilnosti metastaza jetre i omogu}ava dugogodišnje preživljavanje od 40%.
Metode: U ovom preglednom radu su prikazane aktuelne randomizirane studije èiji je cilj omoguaeavanje resektabilnosti metastaza kolorektalnog karcinoma u jetri.
Rezultati: Perioperativna citostatska terapija prema protokolu FOLFOX4 je kompatibilna sa resekcijom metastaza i produžava DFS kod reseciranih pacijenata. Rezultati Crys tal, OPUS iCELIM studije potvrdjuju dugogodišnje preživljavanje kod pacijenata sa primarno neresektabilnim metastazama kolorektalnog karcinoma u jetri koji su odgovorili na perioperativnu kombinovanu citostatsko/imunološku terapiju. Efekat kombinovane primene cetuximab-a i bavazizumab-a sa citostatskom terapijom se vidi kod tumora sa KRAS kodon 12/16/61 wild-typ ekspresijom.
Zakljuèak: Multidisciplinarni pristup bolesniku sa metastazama kolorektalnog karcinoma u jetri omoguaeava posle primene perioperativne kombinovane citostatske/imunoške terapije resektabilnost metastaza i dugogodišnje preživljavanje. Optimalna kombinacija je predmet više studija sa ciljem da se poveaea resektabilnost metastaza kod bolesnika sa kolorektalnim karcinomom.
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